Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Innovations in Controlled Release Formulations
share announcement

Innovations in Controlled Release Formulations

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (1 September 2023) | Viewed by 2221

Special Issue Editor

Dr. Varun Kushwah

E-Mail Website
Guest Editor
Research Center Pharmaceutical Engineering, Inffeldgasse 13, 8010 Graz, Austria
Interests: biomedical science; amorphous solid dispersions; nanoparticles; microspheres

Special Issue Information

Dear Colleagues,

We cordially invite all global scientists to submit their research papers on the topic of "Innovations in Controlled Release Formulations" for publication in our upcoming Special Issue. The aim of this Special Issue is to highlight the latest advances, research, and developments in the field of controlled release formulations for pharmaceuticals, nutraceuticals, and functional foods. We welcome papers that cover various aspects of controlled release systems, including, but not limited to, design, development, characterization, in vitro as well as in vivo evaluation, and commercial applications. Your contribution will provide a valuable addition to the existing knowledge and help advance the field of controlled release formulations. We look forward to receiving your submissions and publishing your research.

Dr. Varun Kushwah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • controlled release
  • drug formulations
  • nanoparticles
  • microparticles
  • pharmaceutical technology
  • modified release
  • patient compliance
  • manufacturing process

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1847 KiB  
Article
Evidence of Reliable Gastro-Resistance of Novel Enteric Ready-to-Fill Capsules Simplifying Pharmaceutical Manufacturing
by Jesús Alberto Afonso Urich, Anna Fedorko, Bettina Hölzer and Johannes Khinast
Pharmaceutics 2023, 15(11), 2592; https://doi.org/10.3390/pharmaceutics15112592 - 06 Nov 2023
Viewed by 1859
Abstract
Developing delayed-release formulations for acid-sensitive actives can be a costly and time-consuming process. However, ready-to-fill functional capsules, such as EUDRACAP® can significantly mitigate these challenges. The in vitro performance of EUDRACAP® enteric was evaluated in two typical delayed-release scenarios: for diclofenac [...] Read more.
Developing delayed-release formulations for acid-sensitive actives can be a costly and time-consuming process. However, ready-to-fill functional capsules, such as EUDRACAP® can significantly mitigate these challenges. The in vitro performance of EUDRACAP® enteric was evaluated in two typical delayed-release scenarios: for diclofenac (a drug that can cause irritation to gastric mucosa), and for omeprazole (a drug susceptible to degradation due to the acidity of gastric fluid). The prototypes were tested in HCl 0.1N according to the USP <711> for at least 2 h and compared to commercial products. The results showed that the performance of EUDRACAP® was below LOD and in compliance with the requirements for drug release in acidic media (NMT 10%). Additionally, the impurities were evaluated after the acidic stress. The low total percentage of impurities of 0.44% for diclofenac (NMT 1.50%) and 0.22% for omeprazole (NMT 2.00%) indicates a very good protection by EUDRACAP®. A comprehensive comparative analysis of the in vitro performance clearly showed the acid protection capability of EUDRACAP® enteric capsules making them a serious alternative to existing enteric dosage forms alternatives. EUDRACAP® is an accessible solution both in large-scale industrial and smaller pharmacy settings. Offering increased accessibility, affordability, and convenience to manufacturers and consumers alike and leading to improved healthcare outcomes. Full article
(This article belongs to the Special Issue Innovations in Controlled Release Formulations)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop